GlassScriptPhysician profile
Stephen F Morley
NPI 1316291396
$4,925.44
in general payments reported to CMS, 2019-2025
21 companies · $936 in 2025
The $936 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $831 · 2022: $1,283 · 2023: $989 · 2024: $887 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,728 · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,727.95 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,539.40 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,042.12 | 2021-2025 | Caplyta |
| Corium, LLC | $316.90 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $296.75 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $225.95 | 2022-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $212.04 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $188.66 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $164.21 | 2022-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $135.39 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $131.85 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $130.09 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $124.28 | 2021-2022 | |
| Axsome Therapeutics, INC. | $103.65 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $69.88 | 2022-2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $64.33 | 2025 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $48.22 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $41.41 | 2023 | Jornay Pm |
| Eisai INC. | $31.26 | 2021 | |
| Bausch Health US, LLC | $21.24 | 2022 | |
| Almatica Pharma LLC | $20.06 | 2022 | |
| Tris Pharma INC | $17.75 | 2025 | Onyda Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Morley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.